6ps8
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='6ps8' size='340' side='right'caption='[[6ps8]], [[Resolution|resolution]] 3.30Å' scene=''> | <StructureSection load='6ps8' size='340' side='right'caption='[[6ps8]], [[Resolution|resolution]] 3.30Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[6ps8]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PS8 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PS8 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6ps8]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PS8 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PS8 FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=JEY:N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide'>JEY</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=JEY:N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide'>JEY</scene></td></tr> | ||
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=YCM:S-(2-AMINO-2-OXOETHYL)-L-CYSTEINE'>YCM</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=YCM:S-(2-AMINO-2-OXOETHYL)-L-CYSTEINE'>YCM</scene></td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MTNR1A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ps8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ps8 OCA], [http://pdbe.org/6ps8 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ps8 RCSB], [http://www.ebi.ac.uk/pdbsum/6ps8 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ps8 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ps8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ps8 OCA], [http://pdbe.org/6ps8 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ps8 RCSB], [http://www.ebi.ac.uk/pdbsum/6ps8 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ps8 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/MTR1A_HUMAN MTR1A_HUMAN]] High affinity receptor for melatonin. Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity. | [[http://www.uniprot.org/uniprot/MTR1A_HUMAN MTR1A_HUMAN]] High affinity receptor for melatonin. Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity. | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Rational structure-based drug design (SBDD) relies on the availability of a large number of co-crystal structures to map the ligand-binding pocket of the target protein and use this information for lead-compound optimization via an iterative process. While SBDD has proven successful for many drug-discovery projects, its application to G protein-coupled receptors (GPCRs) has been limited owing to extreme difficulties with their crystallization. Here, a method is presented for the rapid determination of multiple co-crystal structures for a target GPCR in complex with various ligands, taking advantage of the serial femtosecond crystallography approach, which obviates the need for large crystals and requires only submilligram quantities of purified protein. The method was applied to the human beta2-adrenergic receptor, resulting in eight room-temperature co-crystal structures with six different ligands, including previously unreported structures with carvedilol and propranolol. The generality of the proposed method was tested with three other receptors. This approach has the potential to enable SBDD for GPCRs and other difficult-to-crystallize membrane proteins. | ||
+ | |||
+ | Toward G protein-coupled receptor structure-based drug design using X-ray lasers.,Ishchenko A, Stauch B, Han GW, Batyuk A, Shiriaeva A, Li C, Zatsepin N, Weierstall U, Liu W, Nango E, Nakane T, Tanaka R, Tono K, Joti Y, Iwata S, Moraes I, Gati C, Cherezov V IUCrJ. 2019 Oct 24;6(Pt 6):1106-1119. doi: 10.1107/S2052252519013137. eCollection, 2019 Nov 1. PMID:31709066<ref>PMID:31709066</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 6ps8" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Human]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Batyuk, A]] | [[Category: Batyuk, A]] |
Revision as of 13:09, 25 December 2019
XFEL MT1R structure by ligand exchange from agomelatine to 2-phenylmelatonin.
|
Categories: Human | Large Structures | Batyuk, A | Cherezov, C | Gati, C | Han, G W | Ishchenko, A | Iwata, S | Joti, Y | Li, C | Liu, W | Moraes, I | Nakane, T | Nango, E | Shiriaeva, A | Stauch, B | Tanaka, R | Tono, K | Weierstall, U | Zatsepin, N A | 2-phenyl melatonin | Agomelatine | Complex-lcp method | Drug design | Gpcr | Lcp-sfx | Ligand exchange | Membrane protein | Mt1 | Sbdd | Xfel